Arcellx, Inc.
ACLX
Clasificación en acciones
#2784
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Precio por acción
$115.07
Última sincronización: 2026-05-15
Capitalización bursátil
$6.73B
Cambio (1 día)
0.00%
Cambio (1 año)
32.28%
País
US
Comercio Arcellx, Inc. (ACLX)
Categoría
Healthcare
EPS de Arcellx, Inc. (ACLX)
EPS a fecha de December 2025 TTM: $-4.07
Según los últimos informes financieros y el precio de las acciones de Arcellx, Inc., el EPS actual de la empresa (TTM) es $-4.07. Al final del año 2023, la empresa tenía un EPS de $-1.47 una disminución en comparación con al EPS de 2022, que fue de $-4.28.
Historial de EPS de Arcellx, Inc. desde 2018 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
